Global cost modeling analysis of HIV-1 and HCV viral load assays

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 3, Issue 4, 2003, Pages 383-407

  Elbeik, Tarek ^a   Dalessandro, Ralph ^b   Chen, Yi Ming Arthur ^c   Soutchkov, Serguei V ^d   Loftus, Richard A ^e   Beringer, Scott ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Newbridge Technology   (United States)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d Central Research Institute of Gastroenterology   (Russian Federation)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Professional Habitat Design   (United States)

Author keywords

Bayer VERSANT bDNA; Center of excellence; COBAS; Cost model; Examples; HCV; HIV 1; Labor and supply costs; Resource poor countries; Resource rich countries; Roche AMPLICOR MONITOR

Indexed keywords

VIRUS DNA;

BIOASSAY; COMPUTER PROGRAM; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; EVALUATION; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; LABORATORY TEST; MARKETING; PATIENT MONITORING; POLYMERASE CHAIN REACTION; RESOURCE MANAGEMENT; REVIEW; VIRUS LOAD;

EID: 0041560004     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.3.4.383     Document Type: Review

References (15)

1. Yeni PG, Hammer SM, Carpenter CC et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 10, 222-235 (2002).
2. Dybul M, Fauci AS, Bartlett JG et al. Panel on Clinical Practices for Treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann. Intern. Med. 137, 381-433 (2002).
3. Bartholomew C. Prices of CD4 assays and viral load tests must be reduced for developing countries. Br. Med. J. 323,809-810 (2001).
4. Rabkin M, El-Sadr W, Katzenstein DA et al. Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet 360, 1503-1505 (2002).
5. Hirschel B. Antiretroviral treatment and research in resource-poor countries. Lancet 361, 434-435 (2003).
6. Stephenson J. Cheaper HIV drugs for poor nations bring a new challenge: monitoring treatment. JAMA 288, 151-153 (2002).
7. Schupbach J. Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA. AIDS Rev. 4, 83-92 (2002).
8. Sutthent R, Gaudart N, Chokpaibulkit K et al. p24 Antigen Detection Assay Modified with a Booster Step for Diagnosis and Monitoring of Human Immunodeficiency Virus Type 1 Infection. J. Clin. Microbiol 41, 1016-1022 (2003).
9. Braun J, Plantier JC, Hellot MF et al. A new quantitative HIV load assay based on plasma virion reverse transcriptase activity for the different types, groups and subtypes. AIDS 14, 331-336 (2003).
10. Vergne L, Malonga-Mouellet G, Mistoul I et al. Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J. Acquir. Immune. Defic. Syndr. 29, 165-168 (2002).
11. Adje C, Cheingsong R, Roels TH et al. The UNAIDS HIV Drug Access Initiative, Abidian, Cote d'Ivoire. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. J. Acquir. Immune. Defic. Syndr. 26, 501-506 (2001).
12. Gleaves CA, Welle J, Campbell M et al. Multicenter evaluation of the Bayer VERSANT HIV-1 RNA 3.0 assay: analytical and clinical performance. J. Clin. Virol. 25,205-16 (2002).
13. Triques K, Coste J, Perret JL et al. Efficiencies of four versions of the AMPLICOR HIV-1 MONITOR test for quantification of different subtypes of human immunodeficiency virus Type 1. J. Clin. Microbiol. 37, 110-116 (1999).
14. Elbeik T, Charlebois E, Nassos P et al. Quantitative and cost comparison of ultrasensitive human immunodeficiency virus Type 1 RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor monitor version 1.5. J. Clin. Microbiol. 38, 1113-1120 (2000).
15. Elbeik T, Loftus RA, Beringer S. Healthcare industries' perspective of viral load assays: the VERSANT HIV-1 RNA 3.0 assay. Expert Rev. Mol. Diagn. 2, 275-285 (2002).